Impact of Center for Personalized Diagnostics (CPD) Genomic Testing

Marilyn Schapira, MD, MPH, offers an overview of the oncology genomic testing program at the Center for Personalized Diagnostics at Penn Medicine, which includes comprehensive heme-NGS and solid tumor panels for somatic mutations in AML, brain tumors, GI malignancies, lung malignancies, and melanoma. Dr. Schapira’s discussion also delves into the factors that influence the uptake of CPD testing and treatment decisions among physicians who use the CPD.



Related Links



October 14, 2013

Created by

Penn Physician VideoLink